Skip to content
TheChatArchiveThe Chat Archive
Microsoftwizardlm-70b· MicrosoftHugging Face Arena Human Preference 55K

List 20 or more oncology drugs approved in or after 2020. Show in a markdown table only:…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with OpenChatopenchat-3.5’s answer.
  1. User

    List 20 or more oncology drugs approved in or after 2020. Show in a markdown table only: Order no., Drug name(s), company, indication, year of approval. Sort table by drugname.

  2. Microsoft Assistant
    Order No.Drug Name(s)CompanyIndicationYear of Approval
    1Tivdak (fadolapdotin)Seerave Pharmaceuticals/EisaiEndometrial cancer2021
    2Enhertu (trastuzumab deruxtecan)Daiichi Sankyo, AstraZenecaHER2-positive metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma2020
    3Tepmetko (tepotinib)Merck KGaA, PfizerMetastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations2021
    4LurbinectedinPharmaMarSmall cell lung cancer (SCLC)2020
    5Libtayo (cemiplimab)Regeneron Pharmaceuticals, SanofiAdvanced cutaneous squamous cell carcinoma (CSCC)2021
    6Peptide receptor radionuclide therapy (LuPSMA)NovartisProstate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer2022
    7Sotorasib (Amgen)AmgenKRAS G12C-mutated non-small cell lung cancer (NSCLC)2021
    8Selinexor (Xpovio)Karyopharm TherapeuticsDiffuse large B-cell lymphoma (DLBCL)2020
    9Pirtobrutinib (M2698)Mundipharma/EisaiMantle cell lymphoma (MCL)2022
    10Obinutuzumab (Gazyva)Roche/GenentechCombination with venetoclax for chronic lymphocytic leukemia (CLL)2020
    11Melflufen (Pepaxto)OncopeptidesRelapsed refractory multiple myeloma2021
    12MargetuximabMacroGenicsMetastatic HER2-positive breast cancer2020
    13Masitinib (Kinavet)AB ScienceSystemic mastocytosis2021
    14LeclazaomabApobiologixChronic lymphocytic leukemia (CLL)2022
    15Dostarlimab (Jemperli)GlaxoSmithKline (GSK)dMMR endometrial cancer, mismatch repair deficient solid tumors2021
    16Cibisatamab (M18-1763)MacroGenicsB-cell malignancies2022
    17Briumvi (birodotinib)F. Hoffmann-La RocheEczema vaccinatum or eczema herpeticum2021
    18BimekizumabUCBModerate-to-severe plaque psoriasis2021
    19Belantamab mafodotin (Blenrep)GlaxoSmithKline (GSK)Relapsed or refractory multiple myeloma2020
    20Balversa (erdafitinib)Janssen PharmaceuticalsUrothelial carcinoma with suspected FGFR alterations2020

    Please note that while I strive to provide accurate and up-to-date information, it is always a good idea to check with official sources for the most recent approvals and indications.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.